Literature DB >> 9683296

Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours.

J E Nutt1, J K Mellon, K Qureshi, J Lunec.   

Abstract

The matrix metalloproteinases are a family of enzymes that degrade the extracellular matrix and are considered to be important in tumour invasion and metastasis. The effect of epidermal growth factor (EGF) on matrix metalloproteinase-1 (MMP1) production in two human bladder tumour cell lines, RT112 and RT4, has been investigated. In the RT112 cell line, an increase in MMP1 mRNA levels was found after a 6-h incubation with EGF, and this further increased to 20-fold that of control levels at 24- and 48-h treatment with 50 ng ml(-1) of EGF. MMP2 mRNA levels remained constant over this time period, whereas in the RT4 cells no MMP2 transcripts were detectable, but MMP1 transcripts again increased with 24- and 48-h treatment with 50 ng ml(-1) of EGF. MMP1 protein concentration in the conditioned medium from both cell lines increased with 24- and 48-h treatment of the cells and the total MMP1 was higher in the medium than the cells, demonstrating that the bladder tumour cell lines synthesize and secrete MMP1 protein after continuous stimulation with EGF. MMP1 protein was detected in urine from patients with bladder tumours, with a significant increase in concentration with increased stage and grade of tumour. MMP1 urine concentrations may therefore be a useful prognostic indicator for bladder tumour progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683296      PMCID: PMC2062898          DOI: 10.1038/bjc.1998.467

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay.

Authors:  I Brotherick; T W Lennard; S E Wilkinson; S Cook; B Angus; B K Shenton
Journal:  Cytometry       Date:  1994-07-01

2.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

3.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

4.  [Gene expressions of type IV collagenase and tissue inhibitor of metalloproteinases (TIMP) in human bladder cancers].

Authors:  S Naruo; H Kanayama; M Aki; S Kagawa
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1993-05

5.  Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors.

Authors:  T Nakagawa; T Kubota; M Kabuto; K Sato; H Kawano; T Hayakawa; Y Okada
Journal:  J Neurosurg       Date:  1994-07       Impact factor: 5.115

6.  Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.

Authors:  B Davies; J Waxman; H Wasan; P Abel; G Williams; T Krausz; D Neal; D Thomas; A Hanby; F Balkwill
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

7.  Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma.

Authors:  I M Margulies; M Höyhtyä; C Evans; M L Stracke; L A Liotta; W G Stetler-Stevenson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1992 Sep-Oct       Impact factor: 4.254

8.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

9.  Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay.

Authors:  S C Clifford; D J Thomas; D E Neal; J Lunec
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

10.  Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.

Authors:  P Lipponen; M Eskelinen
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more
  17 in total

1.  A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers.

Authors:  Garrett M Dancik; Yuanbin Ru; Charles R Owens; Dan Theodorescu
Journal:  Cancer Res       Date:  2011-10-19       Impact factor: 12.701

Review 2.  Epidermal growth factor receptor and bladder cancer.

Authors:  A J Colquhoun; J K Mellon
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

Review 3.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

4.  CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.

Authors:  Crystal Johnson-Holiday; Rajesh Singh; Erica Johnson; Shailesh Singh; Cecil R Stockard; William E Grizzle; James W Lillard
Journal:  Int J Oncol       Date:  2011-02-23       Impact factor: 5.650

Review 5.  Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis.

Authors:  Zhiwei Hu; Samira A Brooks; Valérian Dormoy; Chia-Wen Hsu; Hsue-Yin Hsu; Liang-Tzung Lin; Thierry Massfelder; W Kimryn Rathmell; Menghang Xia; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Dustin G Brown; Kalan R Prudhomme; Annamaria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Leroy Lowe; Lasse Jensen; William H Bisson; Nicole Kleinstreuer
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

6.  Association of Matrix Metalloproteinase-1 Genotypes With Bladder Cancer Risk.

Authors:  Cheng-Hsi Liao; Chia-Wen Tsai; Wen-Shin Chang; Zhi-Hong Wang; Chi-Li Gong; Hsi-Chin Wu; Bo-Ren Wang; Shih-Wei Hsu; Wen-Chin Huang; Te-Chun Shen; DA-Tian Bau
Journal:  In Vivo       Date:  2021 Sep-Oct       Impact factor: 2.155

7.  Transcriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer.

Authors:  Kathryn A Bailey; Kathleen Wallace; Lisa Smeester; Sheau-Fung Thai; Douglas C Wolf; Stephen W Edwards; Rebecca C Fry
Journal:  J Can Res Updates       Date:  2012-08-21

8.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

9.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

10.  Matrix Metalloproteinases and Bladder Cancer: What is New?

Authors:  O Rodriguez Faba; J Palou-Redorta; J M Fernández-Gómez; F Algaba; N Eiró; H Villavicencio; F J Vizoso
Journal:  ISRN Urol       Date:  2012-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.